Catalent To Increase Biologic Capabilities

Catalent Pharma Solutions plans to expand its biologics capabilities by relocating to a new, larger facility in Madison, WI, providing increased capacity for cell line and biomanufacturing solutions.
 
The new facility will quadruple capacity in Madison, allowing the company to enhance its offerings in the development and manufacturing of biologic products. The expansion will enhance Catalent’s GPEx cell line engineering technology and process development capabilities, as well as other mammalian cell lines. 
 
The new facility will include three individual cGMP compliant production suites that will increase Phase I and II production capacity to 1,000L bioreactors. Catalent will also transition from stainless steel bioreactors to single use bioreactors.

“Plans for the biologics facility are designed to meet our customers’ needs through improved delivery of integrated services in the areas of biologic development and manufacturing,” said Kent Payne, Ph.D., vice president and general manager of Catalent’s Biologics business. “This is the first step in a series of strategic development initiatives designed to enhance our offerings in this rapidly expanding market.”